BioMarin Pharmaceutical Inc (BMRN): Operating Cash Flow
$827.99M
Year ended 2025-12-31
$857.09M
Trailing 12 months to 2026-06-30
+67.6%
3-year compound annual growth
+57.5%
5-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $827.99M | +44.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $572.84M | +259.7% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $159.26M | -9.5% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $175.90M | -42.2% | 2025-02-24, From 2022-01-01 |
| 2021-12-31 | $304.54M | +256.7% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $85.36M | +76.9% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $48.26M | +138.8% | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $20.21M | n/m | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | -$8.76M | n/m | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | -$227.84M | n/a | 2019-02-28, From 2016-01-01 |
| No annual figure between 2013-12-31 and 2016-12-31. | |||
| 2013-12-31 | -$59.63M | n/m | 2014-02-26, From 2013-01-01 |
| 2012-12-31 | $17.61M | -4.4% | 2014-02-26, From 2012-01-01 |
| 2011-12-31 | $18.41M | n/c | 2014-02-26, From 2011-01-01 |
| 2010-12-31 | $18.75M | -78.6% | 2013-02-26, From 2010-01-01 |
| 2009-12-31 | $87.73M | n/m | 2012-02-22, From 2009-01-01 |
| 2008-12-31 | -$9.18M | n/a | 2011-02-24, From 2008-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $827.99M | +44.5% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $1.56B | +17.6% |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $339.99M | +15.2% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $524.08M | n/m |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $238.50M | -34.3% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $1.36B | -2.9% |
| Royalty Pharma plc (RPRX) | 2025-12-31 | $2.49B | -10.1% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $560.00M | +3.5% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | -$205.48M | n/m |
Compare BMRN, UTHR, AMRX, ALNY side by side · Screen every company in Pharmaceutical Preparations ↗